ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Cosmo Pharmaceuticals NV (PK)

Cosmo Pharmaceuticals NV (PK) (CMOPF)

83,235
1,04
( 1,26% )
Aktualisiert: 20:24:30

Cosmo Pharmaceuticals NV (PK) (CMOPF) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
83,235
( 1,26% )
Gebot
81,37
Fragen
85,02
Volumen
1.612
82,788 Tagesbereich 84,52
75,00 52-Wochen-Bereich 169,90
Marktkapitalisierung
Handelsende
82,20
Handelsbeginn
83,35
Letzte Trade
92
@
83.235
Letzter Handelszeitpunkt
19:54:39
Finanzvolumen
US$ 134.365
VWAP
83,3528
Durchschnittliches Volumen (3 Mio.)
US$ 49.174
Ausgegebene Aktien
16.190.775
Dividendenrendite (LTM)
2,1
Kurs-Gewinn-Verhältnis
-327,26
Gewinn pro Aktie (EPS)
-0,23
Erlöse (LTM)
104,17M
Nettogewinn (LTM)
-3,61M

Über Cosmo Pharmaceuticals NV (PK)

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal... Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Hauptsitz
Dublin, Ireland
Gegründet
1997
Cosmo Pharmaceuticals NV (PK) is listed in the Healthcare sector of the OTC Markets with ticker CMOPF. The last closing price for Cosmo Pharmaceuticals NV (PK) was US$82,20. Over the last year, Cosmo Pharmaceuticals NV (PK) shares have traded in a share price range of US$ 75,00 to US$ 169,90.

Cosmo Pharmaceuticals NV (PK) currently has 16.190.775 shares in issue. The market capitalisation of Cosmo Pharmaceuticals NV (PK) is US$1,35 billion. Cosmo Pharmaceuticals NV (PK) has a price to earnings ratio (PE ratio) of -327.26.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-4.115-4.7109330280587.3588.2488249282.68724352CS
4-22.325-21.1491095112105.56107.80998242890.73030077CS
12-23.933-22.3322260376107.168136.3882377103.84183831CS
26-49.765-37.4172932331133169.982459121.31876208CS
525.3556.8759630200377.88169.975623121.14001427CS
15641.13597.707838479842.1169.941.5541114.47162782CS
260-12.765-13.29687596169.941.5518112.01400897CS

CMOPF - Frequently Asked Questions (FAQ)

What is the current Cosmo Pharmaceuticals NV (PK) share price?
The current share price of Cosmo Pharmaceuticals NV (PK) is US$ 83,235
How many Cosmo Pharmaceuticals NV (PK) shares are in issue?
Cosmo Pharmaceuticals NV (PK) has 16.190.775 shares in issue
What is the market cap of Cosmo Pharmaceuticals NV (PK)?
The market capitalisation of Cosmo Pharmaceuticals NV (PK) is USD 1,35B
What is the 1 year trading range for Cosmo Pharmaceuticals NV (PK) share price?
Cosmo Pharmaceuticals NV (PK) has traded in the range of US$ 75,00 to US$ 169,90 during the past year
What is the PE ratio of Cosmo Pharmaceuticals NV (PK)?
The price to earnings ratio of Cosmo Pharmaceuticals NV (PK) is -327,26
What is the cash to sales ratio of Cosmo Pharmaceuticals NV (PK)?
The cash to sales ratio of Cosmo Pharmaceuticals NV (PK) is 11,5
What is the registered address of Cosmo Pharmaceuticals NV (PK)?
The registered address for Cosmo Pharmaceuticals NV (PK) is Riverside 2, Dublin, Co. Dublin, D02 KV60
What is the Cosmo Pharmaceuticals NV (PK) website address?
The website address for Cosmo Pharmaceuticals NV (PK) is www.cosmohealthconfidence.com
Which industry sector does Cosmo Pharmaceuticals NV (PK) operate in?
Cosmo Pharmaceuticals NV (PK) operates in the Pharmaceuticals sector

CMOPF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen